38,291 results match your criteria Osteosarcoma


Long noncoding RNA taurine-up regulated gene 1 for the prognosis of osteosarcoma: A protocol for meta-analysis and bioinformatics analysis.

Medicine (Baltimore) 2021 Jun;100(24):e26182

Department of Orthopedics and Soft Surgery, Gansu Cancer Hospital, Lanzhou, Gansu Province, China.

Background: In recent years, a variety of long noncoding RNA (lncRNA) has been confirmed to be involved in the initiation and progression of osteosarcoma. Taurine-up regulated gene 1 (TUG1) plays an important role in the formation, invasion, and metastasis of osteosarcoma. Therefore, perhaps TUG1 is a potential biomarker for the prognosis of patients suffering from osteosarcoma. Read More

View Article and Full-Text PDF

Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.

Cancer Res Treat 2021 Jun 14. Epub 2021 Jun 14.

Center for Pediatric Oncology, National Cancer Center, Goyang, Korea.

Purpose: No standard salvage regimen is available for relapsed or refractory sarcoma. We investigated the efficacy and toxicity of the vincristine, irinotecan, and temozolomide combination (VIT) for relapsed or refractory sarcomas of variable histology in children and young adults.

Materials And Methods: We retrospectively reviewed data from the relapsed or refractory sarcoma patients who were treated with VIT. Read More

View Article and Full-Text PDF

Target-activated transcription for the amplified sensing of protease biomarkers.

Chem Sci 2020 Feb 10;11(11):2993-2998. Epub 2020 Feb 10.

State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan Provincial Key Laboratory of Biomacromolecular Chemical Biology, Hunan University Changsha 410082 P. R. China

Signal amplification is an effective way to achieve sensitive analysis of biomarkers, exhibiting great promise in biomedical research and clinical diagnosis. Inspired by the transcription process, here we present a versatile strategy that enables effective amplification of proteolysis into nucleic acid signal outputs in a homogeneous system. In this strategy, a protease-activatable T7 RNA polymerase is engineered as the signal amplifier and achieves 3 orders of magnitude amplification in signal gain. Read More

View Article and Full-Text PDF
February 2020

A Targeted Erythrocyte Membrane-Encapsulated Drug-Delivery System with Anti-osteosarcoma and Anti-osteolytic Effects.

ACS Appl Mater Interfaces 2021 Jun 14. Epub 2021 Jun 14.

Department of Orthopedics, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China.

Chemotherapy is one of the main treatment methods for osteosarcoma. However, conventional chemotherapy lacks targeting properties, and its long-term and extensive use will have serious side effects on patients. For this reason, a multifunctional nanodrug system (V-RZCD) targeting osteosarcoma was developed in this study. Read More

View Article and Full-Text PDF

Radiation recall myositis caused by pazopanib in a patient with refractory osteosarcoma.

Pediatr Blood Cancer 2021 Jun 14:e29147. Epub 2021 Jun 14.

Department of Radiation Oncology and Image-Applied Therapy, Kyoto University, Kyoto, Japan.

View Article and Full-Text PDF

Identification of potential gene signatures associated with osteosarcoma by integrated bioinformatics analysis.

PeerJ 2021 27;9:e11496. Epub 2021 May 27.

Department of Spine Surgery, Tianjin Union Medical Center, Tianjin, China.

Background: Osteosarcoma (OS) is the most primary malignant bone cancer in children and adolescents with a high mortality rate. This work aims to screen novel potential gene signatures associated with OS by integrated microarray analysis of the Gene Expression Omnibus (GEO) database.

Material And Methods: The OS microarray datasets were searched and downloaded from GEO database to identify differentially expressed genes (DEGs) between OS and normal samples. Read More

View Article and Full-Text PDF

miR-877 inhibits the proliferation, migration, and invasion of osteosarcoma cells by targeting gamma-glutamylcyclotransferase.

Endocr J 2021 Jun 12. Epub 2021 Jun 12.

Department of Orthopedics, the Chest Hospital of Hebei Province, Shijiazhuang 050041, China.

Gamma-glutamylcyclotransferase (GGCT) can promote the progression of osteosarcoma (OS). MicroRNAs also play significant roles in regulating the progression of OS. This study was designed to investigate whether miR-877 exerts its function in OS by targeting GGCT. Read More

View Article and Full-Text PDF

Multifunctional magnesium incorporated scaffolds by 3D-Printing for comprehensive postsurgical management of osteosarcoma.

Biomaterials 2021 Jun 4;275:120950. Epub 2021 Jun 4.

Centre for Translational Medicine Research & Development, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China; Key Laboratory of Health Informatics, Chinese Academy of Sciences, Shenzhen, China; CAS-HK Joint Lab of Biomaterials, Shenzhen, China. Electronic address:

Clinical treatment of Osteosarcoma (OS) encounters great challenges of postsurgical tumor recurrence and extensive bone defect. To address these issues, innovative multifunctional PLGA/Mg porous scaffolds were designed for comprehensive postsurgical management of OS. The PLGA/Mg composite scaffolds exhibited several unique features: (1) The multiple functions of Mg particles were explored for the first time to fulfill the requirement for postsurgical management of OS. Read More

View Article and Full-Text PDF

Calotropis procera (Aiton) Dryand (Apocynaceae) as an anti-cancer agent against canine mammary tumor and osteosarcoma cells.

Res Vet Sci 2021 Jun 5;138:79-89. Epub 2021 Jun 5.

Laboratory of Stem Cell, Faculty of Veterinary Medicine and Animal Science, University of São Paulo (USP), São Paulo 05508 270, Brazil.

Our goal was to evaluate phytochemical characterization and the antitumor potential of Calotropis procera. The phytochemical constitution of the crude extract (CE) revealed the presence of flavonoids, glycosides and cardenolide. The MTT assay was used to evaluate the cytotoxicity of CE, methanolic (MF) and ethyl acetate fractions (EAF) of C. Read More

View Article and Full-Text PDF

Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study.

Invest New Drugs 2021 Jun 12. Epub 2021 Jun 12.

Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Background osteosarcoma is a rare, primary malignant bone tumour with limited available treatments for advanced or recurrent disease, resulting in a poor prognosis for patients. TAS-115 is a novel tyrosine kinase inhibitor under investigation in a phase I study in patients with solid tumours. We report data of osteosarcoma patients in the expansion cohort of this ongoing study. Read More

View Article and Full-Text PDF

Distal Tibial Reconstruction in the Management of Primary Bone Tumors in Children and Adolescents.

Foot Ankle Int 2021 Jun 11:10711007211012690. Epub 2021 Jun 11.

Department of Oncology and Surgical Oncology for Children and Youth, Institute of Mother and Child, Warsaw, Poland.

Background: Distal tibial primary bone tumors are rare, and options for limb salvage surgery are limited and challenging. Importantly, local control has shown to be crucial and necessary for cure, and radical surgery is one of the most important components of therapy for some bone sarcomas. We investigated the feasibility and functional and oncological outcomes of distal tibial reconstruction using endoprosthesis in children with malignant bone tumors. Read More

View Article and Full-Text PDF

T-LAK cell-originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma.

Mol Oncol 2021 Jun 11. Epub 2021 Jun 11.

Department of Orthopaedic Surgery, Sarcoma Biology Laboratory, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

T-lymphokine-activated killer (T-LAK) cell-originated protein kinase (TOPK) is an emerging target with critical roles in various cancers; however, its expression and function in osteosarcoma remain unexplored. We evaluated TOPK expression using RNA sequencing and gene expression data from public databases (TARGET-OS, CCLE, GTEx and GENT2) and immunohistochemistry in an osteosarcoma tissue microarray (TMA). TOPK gene expression was significantly higher in osteosarcoma than normal tissues, and directly correlated with shorter overall survival. Read More

View Article and Full-Text PDF

Prognostic factors of chondroblastic osteosarcoma and nomogram development for prediction: A population-based, STROBE-compliant study.

Medicine (Baltimore) 2021 Jun;100(23):e26021

Department of Orthopedics, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Abstract: The present study aimed to develop nomograms to predict survival in patients with chondroblastic osteosarcoma (COS).An analysis was conducted of 320 cases of COS collected from the surveillance, epidemiology, and end results (SEER) database between 2004 and 2015. Independent prognostic factors were screened using univariate and multivariate Cox analyses. Read More

View Article and Full-Text PDF

Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.

Cancer Chemother Pharmacol 2021 Jun 10. Epub 2021 Jun 10.

Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 700-8558, Japan.

Background: Osteosarcoma (OS) is a malignant bone tumor primarily affecting children and adolescents. The prognosis of chemotherapy-refractory OS patients is poor. We developed a tumor suppressor p53-expressing oncolytic adenovirus (OBP-702) that exhibits antitumor effects against human OS cells. Read More

View Article and Full-Text PDF

β-Elemene Enhances the Sensitivity of Osteosarcoma Cells to Doxorubicin via Downregulation of Peroxiredoxin-1.

Onco Targets Ther 2021 3;14:3599-3609. Epub 2021 Jun 3.

Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.

Background: Doxorubicin (Dox) resistance is a primary obstacle for the treatment of osteosarcoma. Meanwhile, β-Elemene was shown to exhibit an anti-proliferative effect on osteosarcoma cells. However, the role of a combination of Dox with β-Elemene on osteosarcoma cells remains unclear. Read More

View Article and Full-Text PDF

Machine learning-based CT radiomics features for the prediction of pulmonary metastasis in osteosarcoma.

Br J Radiol 2021 Jun 11:20201391. Epub 2021 Jun 11.

Department of Medical Imaging, Hematology and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo and Department of Orthopedic surgery, University of Missouri health Care, Columbia, Missouri.

Objective: This study aims to build machine learning-based CT radiomic features to predict patients developing metastasis after osteosarcoma diagnosis.

Methods And Materials: This retrospective study has included 81 patients with a histopathological diagnosis of osteosarcoma. The entire dataset was divided randomly into training (60%) and test sets (40%). Read More

View Article and Full-Text PDF

[Retracted] MicroRNA-124 suppresses the migration and invasion of osteosarcoma cells via targeting ROR2-mediated non-canonical Wnt signaling.

Oncol Rep 2021 Aug 10;46(2). Epub 2021 Jun 10.

Department of Orthopaedics, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China.

Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that certain of the cell Transwell assay data in the article (featured in Figs. 2C and 5B) were strikingly similar to data appearing in different form in other articles by different authors, which were either already under consideration for publication or had already been published elsewhere at the time of the present article's submission. Owing to the fact that the contentious data in the above article were either already under consideration for publication, or had already been published elsewhere, prior to its submission to , the Editor has decided that this paper should be retracted from the Journal. Read More

View Article and Full-Text PDF

[Retracted] MicroRNA-205 acts as a tumor suppressor in osteosarcoma via targeting RUNX2.

Oncol Rep 2021 Aug 10;46(2). Epub 2021 Jun 10.

Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.

Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that certain of the cell Transwell assay data in the article (featured in Fig. 3C and D) were strikingly similar to data that appearing in different form in other articles by different authors at different research institutions, which were already under consideration for publication or had already been published elsewhere at the time of the present article's submission. Owing to the fact that the contentious data in the above article had already appeared in different form in other articles prior to its submission to , the Editor has decided that this paper should be retracted from the Journal. Read More

View Article and Full-Text PDF

MicroRNA-340-5p inhibits the malignant phenotypes of osteosarcoma by directly targeting NRF2 and deactivating the PI3K/AKT pathway.

Eur Rev Med Pharmacol Sci 2021 May;25(10):3661-3669

Department of Pediatrics, Yantai Maternity and Child Care Hospital, Yantaishan Hospital, Yantai, China.

Objective: The aim of the study was to examine the effects and potential mechanisms of miR-340-5p in Osteosarcoma (OS) progression.

Patients And Methods: qRT-PCR was applied to detect expressions of miR-340-5p and NRF2 mRNA. MTT and transwell assay were carried out to determine the roles of miR-340-5p in OS cells viability, invasion and migration. Read More

View Article and Full-Text PDF

[Retracted] MicroRNA-200c inhibits the metastasis of non-small cell lung cancer cells by targeting ZEB2, an epithelial-mesenchymal transition regulator.

Mol Med Rep 2021 Aug 10;24(2). Epub 2021 Jun 10.

Department of Chemotherapy, Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China.

Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that certain of the cell Transwell assay data in the article (featured in Figs. 2C and 4C) were strikingly similar to data appearing in different form in other articles by different authors at different research institutions, which were already under consideration for publication or had already been published elsewhere at the time of the present article's submission [C. Lai , 'MicroRNA‑133a inhibits proliferation and invasion, and induces apoptosis in gastric carcinoma cells via targeting fascin actin‑bundling protein 1', Mol Med Rep 12: 1473‑1478, 2015; and Y. Read More

View Article and Full-Text PDF

Neohesperidin Induces Cell Cycle Arrest, Apoptosis, and Autophagy via the ROS/JNK Signaling Pathway in Human Osteosarcoma Cells.

Am J Chin Med 2021 Jun 2:1-24. Epub 2021 Jun 2.

Department of Orthopedic Surgery, Xiang'an Hospital of Xiamen University, No. 2000, Xiang'an East Road, Xiang'an District Xiamen City, Fujian Province, P. R. China.

Neohesperidin has anti-oxidative and anti-inflammatory properties and exerts extensive therapeutic effects on various cancers. In this study, the osteosarcoma cell lines were exposed to different concentrations of neohesperidin. Cell proliferation and viability were assessed by CCK-8 and colony-formation assays. Read More

View Article and Full-Text PDF

Retraction.

Authors:

J Cell Biochem 2021 Jun 9. Epub 2021 Jun 9.

Retraction: "Inositol polyphosphate-4-phosphatase type II and rucaparib treatment inhibit the growth of osteosarcoma cells dependent on phosphoinositide 3-kinase/protein kinase B pathway," by Dong Li, Jingyan Yang, Huanzhi Ma, Chengliang Sun, Rongjie Feng, J Cell Biochem. 2018; 9899-9909: The above article, published online on 21 August 2018 in Wiley Online Library (https://onlinelibrary.wiley. Read More

View Article and Full-Text PDF

Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation.

Thorac Cancer 2021 Jun 9. Epub 2021 Jun 9.

Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan.

Background: This study was performed to evaluate the clinical outcomes of hybrid treatment involving surgical resection and percutaneous radiofrequency ablation for patients with multiple lung metastases.

Methods: Seventeen patients (6 men, 11 women; median age, 52 years; range, 16-78 years) underwent hybrid treatment involving surgery and radiofrequency ablation to treat multiple lung metastases (median number, 4; range, 2-26) between May 2014 and February 2020. The primary lesions were colorectal carcinoma (n = 9), uterine endometrial carcinoma (n = 3), osteosarcoma (n = 2), renal cell carcinoma (n = 1), glottic carcinoma (n = 1), and fibrolamellar hepatocellular carcinoma (n = 1). Read More

View Article and Full-Text PDF

The 'other' bone sarcomas in Japan: a retrospective study of primary bone sarcomas other than osteosarcoma, Ewing sarcoma and chondrosarcoma, using data from the Bone Tumuor Registry in Japan.

Jpn J Clin Oncol 2021 Jun 9. Epub 2021 Jun 9.

The Department of Rare Cancer Center, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.

Background: To date, no standard treatments for primary bone sarcomas other than those for osteosarcoma, Ewing sarcoma and chondrosarcoma have been developed.

Methods: The clinical characteristics and prognostic factors of 330 patients with primary bone sarcomas other than osteosarcoma, Ewing sarcoma and chondrosarcoma, listed in a nationwide tumour registry (Bone and Soft Tissue Tumor Registry in Japan) were investigated. The effects of adjuvant chemotherapy were determined by comparing the outcomes of patients with non-metastatic bone tumours who received surgery plus chemotherapy with those of patients who underwent surgery alone. Read More

View Article and Full-Text PDF

Retraction.

Authors:

J Cell Physiol 2021 Jun 8. Epub 2021 Jun 8.

Retraction: "Nimotuzuma restrains proliferation and induces apoptosis in human osteosarcoma cells by regulation of EGFR/PI3K/AKT signal pathway," by Meihan Liu, Jingzhe Zhang, Hang Dong, Wenjun Wang, J Cell Physiol. 2019; 20879-20887: The above article, published online on 18 April 2019 in Wiley Online Library (https://onlinelibrary.wiley. Read More

View Article and Full-Text PDF

A small-cohort study on tumor recurrence and surgery-related complications associated with proximal fibular tumors and the potential utility of biopsy.

J Clin Transl Res 2021 Feb 25;7(1):108-115. Epub 2021 Feb 25.

Department of Radiology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei Province 050051, PR China.

Aim: The aim of the study was to assess the incidence of tumor recurrence, iatrogenic peroneal nerve injury, and wound healing problems in a small cohort of patients with proximal fibular tumors who had undergone surgery, and to determine the relative risk of pre-operative biopsies on these outcome variables.

Methods: The study entailed a retrospective single-center analysis of patients with a histologically confirmed tumor in the proximal fibula who had undergone surgery at our institute between 2004 and 2019 ( = 66). The accuracy of diagnosis based on pre-operative biopsy ( = 10) was compared to the histological diagnosis based on resection specimens. Read More

View Article and Full-Text PDF
February 2021

Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma.

Ther Adv Musculoskelet Dis 2021 18;13:1759720X21995069. Epub 2021 Feb 18.

Department of Orthopedic Surgery, David Geffen School of Medicine at UCLA, 615 Charles E. Young Dr. South, Los Angeles, CA 90095, USA.

Background: Overexpression of cyclin-dependent kinase 7 (CDK7) is a well-known pathogenic feature of various malignancies and a sign of a more dismal prognosis. As relatively little is known about CDK7 in osteosarcoma, we elected to evaluate its expression, prognostic value, and function.

Methods: We began by analyzing the publicly available data sets on CDK7 expression, including RNA sequencing data from the and the . Read More

View Article and Full-Text PDF
February 2021

CircPRDM2 Contributes to Doxorubicin Resistance of Osteosarcoma by Elevating EZH2 via Sponging miR-760.

Cancer Manag Res 2021 2;13:4433-4445. Epub 2021 Jun 2.

Department of Spine Surgery, Tianjin Union Medical Center, Tianjin, 300121, People's Republic of China.

Background: Circular RNAs (circRNAs) are implicated in the chemoresistance of human cancers. However, the functions of circRNA PR/SET domain 2 (circPRDM2) in the resistance of osteosarcoma (OS) to doxorubicin (DXR) are unknown.

Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) assay was conducted to determine the levels of circPRDM2, microRNA-760 (miR-760) and enhancer of zeste homolog 2 (EZH2). Read More

View Article and Full-Text PDF

CircFAT1 is Overexpressed in Colorectal Cancer and Suppresses Cancer Cell Proliferation, Invasion and Migration by Increasing the Maturation of miR-10a.

Authors:
Meng Liu

Cancer Manag Res 2021 1;13:4309-4315. Epub 2021 Jun 1.

Department of Oncology, China-Japan Friendship Hospital, Beijing, 100029, People's Republic of China.

Purpose: It has been reported that circFAT1 plays opposite roles in gastric cancer and osteosarcoma. This study aimed to explore the involvement of circFAT1 in colorectal cancer (CRC).

Patients And Methods: Paired CRC and non-tumor tissues from 64 CRC patients were subjected to RNA preparations and RT-qPCRs to determine the expression of circFAT1, premature miR-10a, and mature miR-10a. Read More

View Article and Full-Text PDF

Recognize the role of CD146/MCAM in the osteosarcoma progression: an in vitro study.

Cancer Cell Int 2021 Jun 8;21(1):300. Epub 2021 Jun 8.

Department of Orthopedic Surgery, The First Affiliated Hospital, Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, 150001, China.

Background: Osteosarcoma (OS) is a common malignant bone tumor with poor prognosis. We previously reviewed that CD146 is correlated with multiple cancer progression, while its impact on OS is currently not systematically studied.

Methods: MG63 was transfected with lentivirus to express CD146 ectopically, and anti-CD146 neutralizing antibody ab75769 was used to inhibit 143B. Read More

View Article and Full-Text PDF